Company intelligence / Profile preview

Ehave

Ownership: Private
Development stage: Commercial

Overview

Ehave develops healthcare technology platforms and novel psychedelic compounds aimed at improving mental health outcomes. The company focuses on engineering new treatment protocols and leveraging clinical data to optimize patient care. It has launched a precision medicine platform designed to support clinical research into psychedelics-based therapies. No specific drug candidates have reached advanced clinical stages or commercialization as of the latest public information.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule (novel psychedelic compounds)Device (digital health platforms for clinical research and patient monitoring)Non-pharmacological therapy (treatment protocols leveraging digital tools)
Industry: Biotech

Drug pipeline

1 asset

ketamine

Commercial

Indications: Alcohol Use Disorder

Partnerships

Collaborates with a network of scientists and mental health professionals

Beyond the preview

Go deeper on Ehave.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ehave.

Explore the full profile